Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 3,621 matching trials from the live ClinicalTrials.gov search.
Conditions
Lung Cancer
Interventions
SBRT 40.0 Gy, SBRT 42.5 Gy, SBRT 45.0 Gy, SBRT 47.5 Gy, SBRT 50.0 Gy, SBRT 52.5 Gy, SBRT 55.0 Gy, SBRT 57.5 Gy, SBRT 60.0 Gy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
57
States / cities
Peoria, Arizona • Scottsdale, Arizona • Burbank, California + 50 more
Conditions
Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
Interventions
AZD1775, AZD1775 Matching Placebo, pemetrexed, carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Englewood, Colorado • Fort Myers, Florida • Orlando, Florida + 5 more
Conditions
Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer, Bronchioloalveolar Lung Carcinoma
Interventions
Bevacizumab, Carboplatin, Cixutumumab, Paclitaxel
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
165
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 122 more
Conditions
Metastatic Malignant Neoplasm in the Lung, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Cisplatin, Pharmacological Study
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Non-Small Cell Lung Cancer
Interventions
Dupilumab, Cemiplimab
Biological
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms
Interventions
V941, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Gilbert, Arizona • Duarte, California • San Francisco, California + 7 more
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
nivolumab, ipilimumab, durvalumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
925 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
24
States / cities
La Jolla, California • San Francisco, California • Lone Tree, Colorado + 16 more
Conditions
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Gene Mutation, NFE2L2 Gene Mutation
Interventions
Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Placebo, Folic acid 400 -1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg
Drug · Biological · Dietary Supplement
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 86 more
Conditions
Breast Cancer, Non-Small Cell Lung Cancer, Melanoma, Colorectal Cancer, Pancreatic Cancer, Prostate Adenocarcinoma, Glioma, Primary Solid Tumors
Interventions
131-I-TM-601 (chlorotoxin)
Drug
Lead sponsor
TransMolecular
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 2 more
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Azacitidine, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Completed Phase 2 Interventional Results available

Etirinotecan Pegol (NKTR-102) in NSCLC

NCT01773109
Conditions
Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
Interventions
Etirinotecan pegol (NKTR-102)
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
Ponatinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Locally Advanced or Metastatic Non Small Cell Lung Cancer
Interventions
Rociletinib
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
39
States / cities
Duarte, California • Fountain Valley, California • Los Angeles, California + 32 more
Conditions
Non-small Cell Lung Cancer
Interventions
45 Gray (Gy) regimen
Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
6
States / cities
Greenwich, Connecticut • Guilford, Connecticut • Hamden, Connecticut + 3 more
Conditions
Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
Interventions
Erlotinib Hydrochloride, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
New York, New York • The Bronx, New York
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
Interventions
Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Osimertinib
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
18
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 11 more
Conditions
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Colorectal Cancer, HER2-expressing Non-small Cell Lung Cancer
Interventions
SBT6050, trastuzumab deruxtecan, tucatinib, trastuzumab, capecitabine
Drug
Lead sponsor
Silverback Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Ovarian Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Gastroesophageal Junction Carcinoma, Uterine Cervical Neoplasms, Testicular Neoplasms
Interventions
SGN-ALPV
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Fresno, California • New Haven, Connecticut • Wellington, Florida + 4 more
Conditions
Non Small Cell Lung Cancer, CNS Progression
Interventions
Temozolomide plus Osimertinib, Temozolomide plus Lorlatinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Advanced Cancer
Interventions
Avelumab, Utomilumab, PF-04518600, PD 0360324, CMP-001
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
57
States / cities
Encinitas, California • La Jolla, California • Los Angeles, California + 23 more
Conditions
Lung Cancer
Interventions
celecoxib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment, Sunitinib Malate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
484
States / cities
Anniston, Alabama • Mobile, Alabama • Little Rock, Arkansas + 321 more
Conditions
Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic
Interventions
Docetaxel, Combination of ganetespib and docetaxel
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Tucson, Arizona • Santa Monica, California • Atlanta, Georgia + 5 more
Conditions
Non-Small Cell Lung Cancer (NSCLC), Small-Cell Lung Cancer (SCLC)
Interventions
Blood Draw
Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
945 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 20 more